Prelude Therapeutics
Prelude Therapeutics
PRLD
NASDAQ
0.70
USD
0.00%
About
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates.
Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB.
PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 248.7K |
| Three Month Average Volume | 3.0M |
| High Low | |
| Fifty-Two Week High | 6.8 USD |
| Fifty-Two Week Low | 1.66 USD |
| Fifty-Two Week High Date | 14 Aug 2024 |
| Fifty-Two Week Low Date | 01 Nov 2023 |
| Price and Volume | |
| Current Price | 5.2 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -15.72% |
| Thirteen Week Relative Price Change | 26.20% |
| Twenty-Six Week Relative Price Change | 3.03% |
| Fifty-Two Week Relative Price Change | 11.26% |
| Year-to-Date Relative Price Change | 2.84% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | 35.06% |
| Twenty-Six Week Price Change | 13.29% |
| Five Day Price Change | -3.17% |
| Fifty-Two Week Price Change | 39.41% |
| Year-to-Date Price Change | 21.78% |
| Month-to-Date Price Change | -18.37% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 5.63641 USD |
| Book Value Per Share (Most Recent Quarter) | 4.32362 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 5.63641 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 4.32362 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.95038 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.01852 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.80133 USD |
| Normalized (Last Fiscal Year) | -2.01852 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.01852 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.80133 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.01852 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.80133 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 5.53763 USD |
| Cash Per Share (Most Recent Quarter) | 4.26593 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.99915 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.77835 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.47511 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 11.60% |
| Tangible Book Value (5 Year) | 76.35% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 46.03% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 15.26% |
| EPS Change (Trailing Twelve Months) | 23.47% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -179,337,000 |
| Net Debt (Last Fiscal Year) | -232,935,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 11 |
| Current Ratio (Most Recent Quarter) | 8 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -110,576,000 |
| Free Cash Flow (Trailing Twelve Months) | -106,477,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -48.91% |
| Return on Assets (Trailing Twelve Months) | -51.44% |
| Return on Assets (5 Year) | -47.21% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -56.33% |
| Return on Equity (Trailing Twelve Months) | -58.45% |
| Return on Equity (5 Year) | -57.69% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -53.60% |
| Return on Investment (Trailing Twelve Months) | -55.69% |
| Return on Investment (5 Year) | -51.07% |